Identity
Figure 2. RT-PCR analysis of the expression of hST6GalNAc I in various human cancer lines
The shorter cDNA shows a nucleotide sequence identical to that of the longer form except for the lack of a 234 bp segment at nucleotide positions 652-885 (relative to the ATG of the long-form (# Y11339)). The short-form cDNA would encode a protein that lacks a 78 amino acid fragment at positions 218-295 in the catalytic region (Ikehara et al., 1999) .
Pseudogene
No ST6GalNAc I pseudogene has been identified in the human genome.
Protein

Note
CMP-NeuAc:
N-acetyl-galactosaminide-alpha1-OSer/Thr alpha2,6-sialyltransferase 1; synonyms: SIAT7A, HSY11339, hSTYI, ST6GalNAc I
Description
The human ST6GalNAc I (EC 2.4.99.3, CAZy Family GT29, CMP-NeuAc R-GalNAc-alpha1-O-Ser/Thr alpha2,6-sialyltransferase, with R = H, Gal-beta1-3, or NeuAc-alpha2-3Gal-beta1-3) is a 600 AA type II membrane-bound sialyltransferase. It shares the same typical organization with other Golgi glycosyltransferases with a short N-terminal domain in the cytoplasm of the cell, a trans-membrane domain (TMD), an unusually long stem region and a catalytic domain oriented in the lumen of Golgi cisternae. The enzyme possess the 4 signature motifs (sialylmotifs L, S, VS and motif III) of mammalian sialyltransferases (Harduin-Lepers et al., 2005; Jeanneau et al., 2004) and the ST6GalNAc A family-motifs (Patel Balaji, 2006) . No 3D structure is available. The enzyme transfers a sialic acid (N-acetylneuraminic acid) from CMPNeuAc in the 6-position of a GalNAc residue linked to a serine or a threonine residue of a mucin-type glycopeptide or glycoprotein. The human ST6GalNAc I accepts the following structures as acceptor substrate: GalNAc-alpha-O-Ser/Thr, Gal-beta1-3GalNAc-alpha-O-Ser/Thr and Neu5Ac-alpha2-3Gal-beta1-3GalNAc-alpha-O-Ser/Thr (Ikehara et al., 1999) .
Expression
The stable transfection of MDA-MB-231 or T47D breast cancer cells with an expression vector encoding ST6GalNAc I induces the expression of STn antigen at the cell surface, which is carried by several high molecular weight membrane bound O-glycoproteins, including MUC1 Julien et al., 2005) . Sialyl-Tn expression is associated with morphological changes, decreased growth and adhesion, and increased cell migration of sialyl-Tn positive clones. STn positive MDA-MB-231 breast cancer cells exhibit an increased tumor growth in SCID mice (Julien et al., 2006) . The MKN45 gastric cell line stably transfected with the full length ST6GalNAc-I also showed high expression of Sialyl-Tn antigen (Marcos et al., 2004) . In breast carcinomas, a complete correlation between the expression of ST6GalNAc-I and the expression of sialyl-Tn has been shown (Sewell et al., 2006) .
Localisation
ST6GalNAc I is a Golgi-resident glycosyltrans-ferase.
Function
The Human ST6GalNAc I is a sialyltransferase involved in the biosynthesis of the carbohydrate moiety of mucin-type O-linked glycan chains, transferring a sialic acid residue in 6-position of the first GalNAc residue linked to the peptide aglycone. ST6GalNAc I is particularly involved in the biosynthesis of the sialylTn antigen (STn, NeuAc-alpha2-6GalNAc-alpha1-OSer/Thr) and also participates to the biosynthesis of sialyl-6-T (Gal-beta1-3[NeuAc-alpha2-6]GalNAcalpha1-O-Ser/Thr) and disialyl-T antigens (NeuAcalpha2-3Gal-beta1-3[NeuAc-alpha2-6]GalNAc-alpha1-O-Ser/Thr) (Figure 4 ). ST6GalNAc I compete with Oglycans elongating glycosyltransferases and prevent cancer cells to exhibit longer O-glycans. While fetal and normal adult tissues weakly express STn, the antigen is over-expressed in a wide range of epithelial cancers and is considered as a good maker of tumor. 3) -N-acetylgalactosaminide Delannoy P, The prognostic value of STn expression has been widely studied, especially in gastric, colorectal, ovarian and breast cancers, and is correlated to a decreased survival of the patients.
Homology
ST6GalNAc I is a sialyltransferase (GT-family #29 in the CAZy classification) belonging to the ST6GalNAc family. The amino acid sequence in the catalytic region of human ST6GalNAc I (250 amino acid residues from the C-terminal end) shows sequence identity to mouse ST6GalNAc I (85%), chick ST6GalNAc I (67.2%), 62% homology to human ST6GalNAc II, 36.4% to human ST6GalNAc III, 35.5% to human ST6GalNAc IV, 37.6% to human ST6GalNAc V, and 36.6% to human ST6GalNAc VI.
Mutations
Note Mutation analysis showed a heterozygous transition (g.136T→C) leading to p.V80A with a frequency of 9.3% in 32 unrelated control individuals. No other exonic sequence variations were found. In addition, one intronic (g.IVS8-24G→A) and one 3' UTR SNP (g.1653A→G) was found (Meuleman et al., 2001 ).
Implicated in
Note ST6GALNAC1 encodes a specific CMP-Neu5Ac: GalNAc a2,6-sialyltransferase termed ST6GalNAc I responsible for the biosynthesis of sialyl-Tn (STn) -N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3) -N-acetylgalactosaminide Delannoy P, Atlas Genet Cytogenet Oncol Haematol. 2009; 13(1) antigen (Ikehara et al., 1999) . STn is over-expressed in a wide range of epithelial cancers and is considered as a good tumoral maker. However, its pattern of expression varies according to the cell morphology and differentiation, which depend on the cancer type. STn seems to be related to invasive behavior and metastatic potential of the cancer cells, while the involved mechanisms remain unclear. The prognostic value of STn expression has been widely studied, especially in pancreas, gastric, colorectal, and ovarian cancers and breast cancers. For all the cases, the antigen detection is correlated to a decreased survival of the patients.
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Pancreas Cancer
Note Enhanced expression of Tn and STn antigens is usually observed in pancreas cancer. STn is expressed in intraepithelial neoplasms of the pancreas concomitantly with aberrant expression of MUC5AC and MUC6 gastric mucins (Kim et al., 2002) . High serum concentrations of STn are also observed in pancreas carcinomas (Nanashima et al., 1999 ). STn appears to be a more specific tumor marker in pancreas cancer than Tn antigen (Ching et al., 1994) . STn has been also reported in benign pancreatic intraepithelial neoplasia stage III (PanIN3), the last histologic grade relevant to benign tumor before that the tumor become invasive (Hruban et al., 2000; Kim et al., 2002) . Prognosis Poor, decreased survival of the patients.
Gastric Cancer
Note
STn antigen is over-expressed in gastric carcinomas and associated with MUC1 mucin VNTR polymerphism (Santos-Silva et al., 2005) . STn is also a useful predictor of poor prognosis in patients with advanced stomach cancer (Terashima et al., 1998) . In particular, pre-operative serum levels of STn predict liver metastasis and poor prognosis in patients with gastric cancer (Nakagoe et al., 2001) . STn is able to modulate the malignant phenotype inducing a more aggressive cell behavior, a decreased cell-cell aggregation and an increased ECM adhesion, migration and invasion (Pinho et al., 2007) . However, the expression of ST6GalNAc I is low in gastric carcinoma cell lines, in accordance with the low/absent expression of the STn (Ogata et al., 2001) . Prognosis Poor, decreased survival of the patients.
Colorectal Cancer
Note STn is strongly expressed in a large number of colorectal carcinomas. However, not correlation was found between STn antigen tissue expression and ST6GalNAc I activity levels in colorectal cancer, in spite of the overexpression of the antigen in tumorous and transitional tissue (Vázquez-Martìn et al., 2004) .
The activity of core 1 beta3-Gal-transferase seems to be an important determinant of the STn phenotype of colon cancer cells (Brockhausen et al., 2001) . Cell surface-expressed STn in colon cancer is predominantly carried on high molecular weight splice variants of CD44 (Singh et al., 2001 ). Pre-operative serum level of STn predicts recurrence after curative surgery in node-negative colorectal cancer patients (Takahashi et al., 1993) . Prognosis Poor, decreased survival of the patients
Breast Cancer
Note ST6GalNAc I is responsible for the synthesis of the tumor-associated STn O-glycan in human breast cancer (Sewell et al., 2006) . However, established breast cancer cell-lines express neither ST6GalNAc I nor STn . Stable transfection of MDA-MB-231 cells with ST6GalNAc I cDNA induces STn antigen expression together with important modifications of the O-glycosylation pattern of MUC1 in MDA-MB-231 and T-47D cells Julien et al., 2005) . ST6GalNAc I expression induces a decrease of adhesion and an increase of migration of MDA-MB-231. Moreover, ST6GalNAc I positive clones exhibit an increased tumor growth in SCID mice, suggesting that ST6GalNAc I expression is sufficient to enhance the tumorigenicity of MDA-MB-231 breast cancer cells (Julien et al., 2006) . Prognosis Poor, decreased survival of the patients.
